138 related articles for article (PubMed ID: 19513427)
1. Evaluation of immunotherapy efficiency in mouse CaO-1 ovarian carcinoma treated by vaccines based on dendritic cells.
Sitdikova SM; Kiselevskii MV; Sel'chuk VY; Amandzholov BS; Kurbatova EA; Donenko FV
Bull Exp Biol Med; 2009 Feb; 147(2):226-8. PubMed ID: 19513427
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of specific immunotherapy with mucin containing CA 125 antigen in mice with CaO 1 ovarian carcinoma.
Amandzholov BS; Sitdikova SM; Lebedin YS; Chukanov SV; Toptygin AY; Manzyuk LV; Donenko FV
Bull Exp Biol Med; 2000 Apr; 129(4):383-5. PubMed ID: 10977928
[TBL] [Abstract][Full Text] [Related]
3. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive action of dendritic cells sensitized by oligodeoxynucleotides and CA125 on human OVCAR3 ovarian carcinoma xenografts in nude mice].
Ye M; Li N; Huang X; Wang D; Shang J
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(15):1193-5. PubMed ID: 24924723
[TBL] [Abstract][Full Text] [Related]
5. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
6. Understanding dendritic cell immunotherapy in ovarian cancer.
Drakes ML; Stiff PJ
Expert Rev Anticancer Ther; 2016 Jun; 16(6):643-52. PubMed ID: 27078511
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.
Tanyi JL; Chu CS
Immunotherapy; 2012 Oct; 4(10):995-1009. PubMed ID: 23148752
[TBL] [Abstract][Full Text] [Related]
8. Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care.
Bapsy PP; Sharan B; Kumar C; Das RP; Rangarajan B; Jain M; Suresh Attili VS; Subramanian S; Aggarwal S; Srivastava M; Vaid A
Cytotherapy; 2014 Feb; 16(2):234-44. PubMed ID: 24438902
[TBL] [Abstract][Full Text] [Related]
9. [Active cellular immunotherapy of ovarian cancer using dendritic cells].
Brtnicky T; Podrazil M; Bartunkova J; Spíšek R; Rob L
Ceska Gynekol; 2012 Jun; 77(3):215-20. PubMed ID: 22779721
[TBL] [Abstract][Full Text] [Related]
10. Immunosensitization with a Bcl-2 small molecule inhibitor.
Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
[TBL] [Abstract][Full Text] [Related]
11. In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells.
Schmitt WE; Stassar MJ; Schmitt W; Little M; Cochlovius B
J Cancer Res Clin Oncol; 2001; 127(3):203-6. PubMed ID: 11260867
[TBL] [Abstract][Full Text] [Related]
12. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
Kandalaft LE; Chiang CL; Tanyi J; Motz G; Balint K; Mick R; Coukos G
J Transl Med; 2013 Jun; 11():149. PubMed ID: 23777306
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell-derived exosomes elicit tumor regression in autochthonous hepatocellular carcinoma mouse models.
Lu Z; Zuo B; Jing R; Gao X; Rao Q; Liu Z; Qi H; Guo H; Yin H
J Hepatol; 2017 Oct; 67(4):739-748. PubMed ID: 28549917
[TBL] [Abstract][Full Text] [Related]
14. [Effect of dendritic cell autovaccine on the treatment outcome in patients with ovarian cancer].
Khranovskaia NN; Grinevich IuA; Potebnia GP; Vorod'eva LI; Svintsitskiĭ VS; Tsin NP; Skachkova OV; Sit'ko VV; Lisovenko GS; Tanacienko OA; Svergun NN; Mel'nik VA; Gorbach AI; Nikulina VV
Vopr Onkol; 2012; 58(6):781-6. PubMed ID: 23600304
[TBL] [Abstract][Full Text] [Related]
15. [Progress on the study of ovarian carcinoma vaccine ].
Peng P; Shen J
Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):500-2. PubMed ID: 15347482
[No Abstract] [Full Text] [Related]
16. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
17. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
18. Failure of cancer vaccines: the significant limitations of this approach to immunotherapy.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 2000; 20(4):2665-76. PubMed ID: 10953341
[TBL] [Abstract][Full Text] [Related]
19. Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125.
Wagner U; Schlebusch H; Köhler S; Schmolling J; Grünn U; Krebs D
Hybridoma; 1997 Feb; 16(1):33-40. PubMed ID: 9085126
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors.
Kamigaki T; Kaneko T; Naitoh K; Takahara M; Kondo T; Ibe H; Matsuda E; Maekawa R; Goto S
Anticancer Res; 2013 Jul; 33(7):2971-6. PubMed ID: 23780988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
